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INTRODUCTION
Diabetic nephropathy is the leading cause of chronic kid-
ney disease in Korea, and accounts for 43% of new dialysis
patients in 2004. Nephropathy complicates only 20-40% of
cases of type 2 diabetes, which suggests several genetic fac-
tors would play an important role in the development of ne-
phropathy.
Recently, inflammatory cells, especially macrophages and
related chemokines, are suggested to be involved in the devel-
opment and progression of diabetic nephropathy (1). In strep-
tozotocin-induced diabetic rat model, hyperglycemia is fol-
lowed by early macrophage recruitment (2). Also, macrophage
infiltration is observed during the moderate stage of diffuse
diabetic glomerulosclerosis in the kidney biopsy specimen
from diabetic patients (3). Infiltrated macrophages release
various inflammatory mediators, such as IL-1, TNF- , and
TGF- that result in inflammation, interstitial fibrosis, and
finally permanent kidney damage.
MCP-1 (Monocyte chemoattractant protein-1) and RAN-
TES (regulated upon activation, normal T-cell expressed and
secreted) are the most potent chemokines that recruit mono-
cyte/macrophages to the damaged tissues. A high glucose
concentration in the culture medium stimulated the MCP-
1 expression in human mesangial cells (4). Urinary MCP-1
levels were significantly elevated in patients with diabetic
nephropathy and advanced tubulointerstitial lesions. More-
over, urinary levels of MCP-1 were well correlated with the
number of CD68-positive infiltrating cells in the intersti-
tium (5). In addition, ACE inhibitor, lisinopril treatment
for one year improved renal function, reduced proteinuria,
and significantly decreased urinary MCP-1 levels in patients
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MCP-1 and RANTES Polymorphisms in Korean Diabetic End-Stage
Renal Disease
Macrophage infiltration has been observed in the renal biopsy specimens of diabetic
nephropathy (DN), and hyperglycemic state stimulates the renal expression of RA-
NTES (regulated upon activation, normal T-cell expressed and secreted) and MCP-
1 (monocyte chemoattractant protein-1). Upregulation of RANTES and MCP-1 with
infiltrating macrophages may play a crucial role in the development and progres-
sion of DN. Genetic polymorphisms of RANTES and its receptors were reported to
be independent risk factors for DN. We genotyped single nucleotide polymorphism
(SNPs) in the MCP-1 G-2518A, CCR2 G46295A, RANTES C-28G and G-403A in
177 diabetic end-stage renal disease (ESRD) patients and 184 patients without
renal involvement (controls) in order to investigate the effects of these SNPs on
DN in Korean patients with type 2 DM. There were no differences in the frequen-
cies of SNPs and the distribution of haplotypes of RANTES promoter SNPs bet-
ween two groups. In conclusion, there were no associations of MCP-1, CCR2 and
RANTES promoter SNPs with diabetic ESRD in Korean population. Prospective
studies with clearly-defined, homogenous cohorts are needed to confirm the effect
of these genetic polymorphisms on DN.
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with diabetic nephropathy (6). All of these observations sug-
gest that macrophages and associated chemokines may be
involved in the development and progression of diabetic
nephropathy.
Recently, RANTES promoter single nucleotide polymor-
phism (SNP) -28G genotype and its major receptor, chemo-
tactic cytokine receptor 5 (CCR5) promoter 59029A geno-
type were shown to be associated with diabetic nephropathy
in patients with type 2 diabetes (7, 8). However, effects of
MCP-1 and its receptor CCR2 polymorphisms have not been
fully assessed so far on diabetic nephropathy.
The authors investigated the effects of these SNPs-MCP-
1, CCR2 and RANTES-on diabetic nephropathy in Korean
patients with type 2 diabetes. 
MATERIALS AND METHODS
Subjects
We studied 361 unrelated patients with type 2 diabetes
comprising two groups according to the following criteria:
1) control subjects (n=184), patients with diabetic retinopa-
thy and a duration of type 2 diabetes of >15 yr, but without
signs of renal involvement, i.e., a urinary albumin to creati-
nine ratio of <30 mg/g and with a creatinine clearance (using
the Cockroft-Gault formula) of >60 mL/min/m2; or 2) ESRD
cases (n=177), patients with diabetic retinopathy and ESRD
due to type 2 diabetes as indicated by a creatinine clearance
rate of <15 mL/min/m2 or who were on renal replacement
therapy. We excluded subjects with ESRD with any one of
the following criteria: 1) those without retinopathy; 2) a con-
sistent hematuria history before renal failure; 3) no past his-
tory of proteinuria before renal failure; 4) contracted kidneys
on imaging study; and 5) those suspected to have non-dia-
betic glomerular diseases. Patients with family history of dia-
betic ESRD were also excluded because the unknown genetic
factors specific to those families could interfere the effects of
polymorphisms. All subjects enrolled in this study were of
Korean ethnicity. Type 2 diabetes was diagnosed based in
the World Health Organization criteria. Subjects positive for
GAD antibodies and who started insulin treatment within 1
yr of diagnosis, and those who were prone to ketosis were ex-
cluded. The Institutional Review Board of the Clinical Re-
search Institute at Seoul National University Hospital ap-
proved the study protocol, and informed consent for genetic
analysis was obtained from each subject.
Methods
Genomic DNA was extracted from peripheral blood cells,
and then we genotyped G-2518A in the MCP-1 promoter
region, G46295A in the CCR2 gene, C-28G and G-403A
in the promoter region of the RANTES gene. Briefly, for the
genotyping of polymorphic sites, amplification and exten-
sion primers were designed for single-base extension (SBE)
(9). Primer extension reactions were performed with SNaP-
shot ddNTP Primer Extension Kit (Applied Biosystems,
Foster City, CA, U.S.A.). To clean up the product of the pri-
mer extension reaction, one unit of SAP was added to the
reaction mixture and the mixture was incubated at 37℃ for
1 hr, followed by 15 min at 72℃ for enzyme inactivation.
The DNA samples, containing extension products, and Genes-
can 120 Liz size standard solutions were added to Hi-Di for-
mamide (Applied Biosystems). The mixture was incubated
at 95℃ for 5 min, followed by 5 min on ice and then ana-
lyzed by electrophoresis on the ABI Prism 3100 Genetic
Analyzer (Applied Biosystems). The results were analyzed
using the software GeneScan and Genotyper (Applied Bio-
systems). Haplotypes for the SNP C-28G and G-403A in
the RANTES gene were determined using the PHASE (ver-
sion 2.3) software (10).
Statistical analysis
The data were expressed as means±standard deviation.
Chi-square test and Fisher’s exact test, as appropriate, were
used to test differences between the ESRD and control groups
for significance. To assess the relationship of genotypes with
nephropathy, multiple logistic regression analysis was per-
formed using the SPSS statistical package (SPSS Inc. Chica-
go, IL, U.S.A.). A p value less than 0.05 was considered sta-
tistically significant.
RESULTS
We studied 361 patients with type 2 diabetes, comprising
177 patients with ESRD (ESRD group) and 184 patients
with diabetic retinopathy and duration of type 2 diabetes of
>15 yr but without evidence of renal disease (the control
group). The clinical characteristics of these groups are sum-
marized in Table 1. There were significant differences in the
male-to-female ratio (1.46:1 in ESRD vs. 0.61:1 in controls,
p<0.001) and mean (±SD) age (61±9 in ESRD vs. 64±7
in controls, p=0.002). Systolic/diastolic blood pressure of the
ESRD groups was also higher than those of control groups
(150±21/83±12 mmHg vs. 131±16/77±9 mmHg,
p<0.001).
Genotype distributions for the polymorphisms of MCP-1
G-2518A, CCR2 G46295A, RANTES C-28G and G-403A
are presented in Table 2. The distributions of these genotypes
were in Hardy-Weinberg equilibrium, indicating a lack of
selection for or against each. The genotype frequencies of
those SNPs were not different between two groups.
We observed six genotypes of RANTES C-28G and G-
403A polymorphisms. RANTES -28G/G was not found in
subjects with the -403G allele, while RANTES -403G/GMCP-1 and RANTES SNPs in Diabetic ESRD 613
was not observed in subjects with the -28G allele. Therefore,
there were three haplotypes of the RANTES promoter region
(haplotypes I, II, and III in Table 3). This is consistent with
the results of previous studies (7, 11). The frequencies of hap-
lotypes I, II, and III in ESRD groups were 63.6%, 20.1%,
and 16.3%, and those in control groups were 58.2%, 25.0%,
and 16.8%, respectively. There were no significant differences
in the frequencies of each genotype and haplotype between
two groups.
DISCUSSION
Macrophages are not only the major effecter cells in innate
immune response but are also one of the central mediators of
renal vascular inflammation, and their accumulation is known
to be one of the characteristic features of diabetic nephropa-
thy (1). Infiltrated macrophages are found within kidney tis-
sues from diabetic nephropathy patients (3), and macrophage-
derived products can induce further inflammation in the dia-
betic kidney. In a streptozotocin-induced diabetic rat model,
macrophages were recruited within glomeruli at the very early
stage of hyperglycemia, and macrophage recruitment was
associated with an increase in alpha chain type IV collagen
mRNA and glomerular hypertrophy (2). In addition, glo-
merular expression of VCAM-1 (vascular cell adhesion mole-
cule-1), ICAM-1 (intracellular adhesion molecule-1), and
MCP-1 increased in advance, which have been shown to be
important in macrophage accumulation and renal injury in
models of nondiabetic and diabetic kidney (12, 13).
MCP-1, also termed monocyte chemotactic and activating
factor (MCAF) or CCL2, is a potent chemokine that is known
to affect both macrophage accumulation and its function. Uri-
nary MCP-1 levels were increased in patients with diabetic
nephropathy and advanced tubulointerstitial lesion and there
were MCP-1 positive cells in the intersititium in the kidney
tissues (5). Also, urinary MCP-1 levels correlate with urinary
excretion level of albumin in human diabetic kidney (14).
Moreover, blockade of the renin-angiotensin system reduced
urinary MCP-1 levels, lowered glomerular expression of
MCP-1, decreased macrophage infiltration, and improved
renal function (6, 15, 16). These findings suggest that reno-
protection conferred by renin-angiotensin blockade is at least
partly dependent on the inhibition of macrophage infiltra-
tion and interstitial fibrosis mediated by MCP-1.
Recently, Chow et al. showed that the macrophage infiltra-
tion and renal injury were markedly suppressed in diabetic
ESRD, end-stage renal disease; BMI, body mass index; SBP, systolic






Gender (M:F) 70:114 105:72 <0.001
Age (yr) 64±76 1 ±9 0.002
Duration of diabetes (yr) 20±51 8 ±8 0.006
BMI (kg/m
2) 23.9±2.6 23.2±2.8 0.015
SBP (mmHg) 131±16 150±21 <0.001
DBP (mmHg) 77±98 3 ±12 <0.001
Fasting plasma glucose (g/dL) 146±43.2 148±57.6 NS
HbA1C (%) 7.7±1.2 7.2±1.5 <0.001
Serum creatinine (mg/dL) 0.8±0.14 7.1±2.41 <0.001
Table 1. Clinical characteristics of control group and end-stage
renal disease group
Genotype data are the number (%) of patients.
MCP-1, monocyte chemoattractant protein-1; CCR2, chemotactic cyto-
kine receptor 5; RANTES, regulated upon activation, normal T-cell exp-






GG 22 (32) 46 (46) 68 (40) 38 (40) 27 (40) 65 (40)
GA 36 (53) 42 (42) 78 (46) 45 (46) 28 (42) 73 (45)
AA 10 (15) 13 (12) 23 (14) 14 (14) 12 (18) 26 (15)
68 (100) 101 (100) 169 (100) 97 (100) 67 (100) 164 (100)
CCR2 G46295A
GG 35 (50) 60 (53) 95 (52) 56 (54) 36 (50) 92 (53)
GA 26 (37) 46 (41) 72 (39) 41 (40) 32 (44) 73 (42)
AA 9 (13) 7 (6) 16 (9) 6 (6) 4 (6) 10 (5)
70 (100) 113 (100) 183 (100) 103 (100) 72 (100) 175 (100)
RANTES C-28G
CC 50 (71) 76 (67) 126 (68) 73 (70) 49 (68) 122 (69)
CG 20 (29) 34 (30) 54 (29) 29 (28) 21 (29) 50 (28)
GG 0 (0) 4 (3) 4 (3) 2 (2) 2 (3) 4 (3)
70 (100) 114 (100) 184 (100) 104 (100) 72 (100) 176 (100)
RANTES G-403A
GG 27 (39) 37 (33) 64 (35) 40 (39) 29 (41) 69 (39)
GA 33 (47) 53 (46) 86 (47) 52 (50) 33 (46) 85 (49)
AA 10 (14) 24 (21) 33 (18) 12 (11) 9 (13) 21 (12)
70 (100) 114 (100) 183 (100) 104 (100) 71 (100) 175 (100)
Table 2. Distributions of MCP-1 promoter -2518, CCR2 46295








I G C 214 (58.2) 225 (63.6)
II A C 92 (25.0) 71 (20.1)
III A G 62 (16.8) 58 (16.3)
Total 368 (100) 354 (100)
Genotype
1 G/G C/C 64 (34.8) 70 (39.5)
2 A/A C/C 11 (6.0) 5 (2.8)
3 A/A G/G 4 (2.2) 4 (2.3)
4 G/A C/C 51 (27.7) 48 (27.1)
5 G/A C/G 35 (19.0) 37 (20.9)
6 A/A C/G 19 (10.3) 13 (7.3)
Total 184 (100) 177 (100)
Table 3. Frequencies of RANTES promoter genotypes and hap-
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MCP-1 (-/-) mice compared to MCP-1 (+/+) mice despite
the equivalent blood glucose and hemoglobin A1c levels (17).
This study further supports the importance of MCP-1 medi-
ated accumulation and activation of macrophage in the devel-
opment of diabetic nephropathy.
RANTES is another chemokine that has been shown to
be important in macrophage recruitment and renal injury.
However, little is known about the pathogenic role in diabet-
ic nephropathy. Previous studies using renal allograft model
showed that Met-RANTES, a chemokine receptor antago-
nist, suppressed recruitment of inflammatory cells, mainly
monocytes, into renal allografts, reduced proteinuria and sig-
nificantly ameliorated glomerulosclerosis, interstitial fibro-
sis, and tubular atrophy (18).
We hypothesized that genetic variability in the expression
of MCP-1 and RANTES may influence the development of
diabetic nephropathy.
There are few studies that examined the associations between
chemokine gene polymorphisms and nephropathy in type 2
DM. Nakajima et al. reported that the RANTES promoter
-28G genotype and the major RANTES receptor, CCR5,
promoter 59029A genotype were associated with the diabetic
nephropathy (7, 8). However, existing data for most of poly-
morphism studies in diabetic nephropathy are inconclusive
because of the small sample size and heterogeneity of type 2
diabetes itself. Therefore, we defined type 2 diabetic patients
with DM duration of more than 15 yr but no signs of renal
involvement as the control group, and patients with DM
ESRD as the nephropathy group in order to improve the
statistical power given the relatively small sample size. It is
well known that about 90% of diabetic individuals have type
2 DM, and within this category no more than 10% can be
accounted for by monogenic forms such as maturity onset
diabetes of the young (MODY) and mitochondrial diabetes
or late-onset autoimmune diabetes of the adult, which is
actually a late-onset type 1 diabetes. Also, 20-30% of pati-
ents with type 2 DM may progress to a significant degree of
renal impairment while remaining normoalbuminuric (19).
It has been suggested that ‘‘age-associated’’ renal senescence,
interstitial fibrosis, and ischemic vascular disease, such as
atherosclerotic involvement of the renal artery and intrarenal
vascular disease may contribute the renal progression (20).
Thus we selected the nephropathy group by the strict clini-
cal criteria, and excluded normoalbuminuric patients with
reduced creatinine clearance from the control group.
To our knowledge, this is the first study investigating the
association between the MCP-1 SNP and diabetic nephropa-
thy in Korea, involving a well-controlled study with clearly-
defined subjects. In the present study, the distribution of
SNPs in the regulatory region of MCP-1, RANTES, and
CCR2 did not differ between the diabetic patients without
nephropathy and the diabetic ESRD patients. This is not
consistent with the previous study from the Japanese popu-
lation (7). Differences in the study design and patient selec-
tion criteria, e.g. normoabuminuria vs. microalbuminuria vs.
macroalbumnuria group, may explain the conflicting result. 
It is also possible that the subjects with ESRD and high risk
genotypes may be excluded from the present study because
of premature mortality due to cardiovascular events. In Cau-
casian type 2 DM patients on hemodialysis, carriers of the
RANTES -403A allele had an 81% higher risk for all-cause
mortality, mainly due to cardiac events (21). Since chemo-
kines and macrophages are important in the development of
atherosclerosis as well as nephropathy, it cannot be ruled out
that high risk genotypes affected not only microvascular but
also macrovascular complications. It may be postulated that
carriers of the RANTES -403A genotype are more subject
to atherosclerosis and premature death due to cardiovascular
diseases before progressing to ESRD, whereas carriers of RA-
NTES -403G genotype live long enough to reach ESRD.
More importantly, the other possibility is that chemokine-
mediated macrophage recruitment might play a pivotal role
in the earlier stage of diabetic nephropathy than the advanced
stage as in our nephropathy group, and other factors may be
involved in the progression of diabetic nephropathy to ESRD.
Subjects in the nephropathy group were slightly younger
and had more male subjects. However, this reflects the real
world, and there were no differences in the genotype frequen-
cies when stratified by sex and age (data not shown).
In conclusion, there were no associations of MCP-1, CCR2
and RANTES promoter SNPs with diabetic ESRD in the
Korean population. Prospective studies with clearly-defined,
homogenous cohorts are needed to confirm the effect of these
genetic polymorphisms on diabetic nephropathy.
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